ADMA Biologics (ADMA) Stock Overview
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ADMA from our risk checks.
ADMA Community Fair Values
Create NarrativeSee what 103 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
ADMA Biologics
55.9% undervalued intrinsic discount
Valuation analysis
View narrativePI
Updated 11 Nov 2024
ADMA Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.23 |
| 52 Week High | US$20.46 |
| 52 Week Low | US$7.21 |
| Beta | 0.77 |
| 1 Month Change | -2.53% |
| 3 Month Change | 8.59% |
| 1 Year Change | -42.71% |
| 3 Year Change | 147.45% |
| 5 Year Change | 615.50% |
| Change since IPO | 8.21% |
Recent News & Updates
Seeking Alpha • Sep 02
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)
Summary ADMA Biologics faces growth deceleration and lowered FY26 revenue guidance, prompting a downgrade to a cautious Hold rating. ASCENIV remains the core growth driver, but BIVIGAM's sharp decline and aggressive revenue targets raise execution risk. DCF valuation yields $9.52/share, just 1.4% above market, highlighting sensitivity to growth assumptions amid a flat topline and rising inventory. Despite low P/E and EV/EBITDA multiples, ADMA's stock is only attractive if optimistic growth and margin assumptions are met. Read the full article on Seeking Alpha
Narrative Update • Jul 01
ADMA: Future Cash Returns From Buybacks Will Counter Legal Overhang
The updated analyst fair value estimate for ADMA Biologics has shifted from $17.00 to $12.00. This reflects revised expectations for revenue growth, profit margins and future P/E assumptions, even as analysts highlight the company's profitable profile, high-growth characterization and insulation from certain U.S. pricing pressures.Recent updates
Seeking Alpha • Sep 02
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)
Summary ADMA Biologics faces growth deceleration and lowered FY26 revenue guidance, prompting a downgrade to a cautious Hold rating. ASCENIV remains the core growth driver, but BIVIGAM's sharp decline and aggressive revenue targets raise execution risk. DCF valuation yields $9.52/share, just 1.4% above market, highlighting sensitivity to growth assumptions amid a flat topline and rising inventory. Despite low P/E and EV/EBITDA multiples, ADMA's stock is only attractive if optimistic growth and margin assumptions are met. Read the full article on Seeking AlphaNarrative Update • Jul 01
ADMA: Future Cash Returns From Buybacks Will Counter Legal Overhang
The updated analyst fair value estimate for ADMA Biologics has shifted from $17.00 to $12.00. This reflects revised expectations for revenue growth, profit margins and future P/E assumptions, even as analysts highlight the company's profitable profile, high-growth characterization and insulation from certain U.S. pricing pressures.
Narrative Update • Jun 17
ADMA: Future Stock Upside Will Rely On Plasma Margin Resilience
The analyst price target for ADMA Biologics has been revised slightly lower, with fair value moving from $18.33 to $17.60 as analysts factor in updated assumptions around revenue growth, profit margins, and a modestly higher future P/E multiple, while still citing the company’s profitable profile, growth potential, and exposure to supportive plasma-derived product dynamics. Analyst Commentary Recent Street research on ADMA Biologics reflects both confidence in the company’s fundamentals and some caution around risks and valuation, giving investors a mixed but useful reference point when thinking about the stock.
Narrative Update • Jun 02
ADMA: Future Cash Returns And Label Expansion Will Support Share Upside
The updated analyst price target for ADMA Biologics moves from $30 to $20, as analysts factor in revised profit margin expectations, a higher discount rate, and a lower assumed future P/E multiple, even as revenue growth forecasts are adjusted. Analyst Commentary Recent Street research on ADMA Biologics shows a mix of caution and optimism, with some firms lowering price targets and others initiating coverage with a constructive view.Narrative Update • May 08
ADMA: Long Term Revenue Outlook And Buybacks Will Support Future Upside
Analysts have trimmed their price targets on ADMA Biologics by roughly one third to about $18.33, citing updated assumptions around growth, profitability, and future P/E multiples following recent initiation, target cuts, and a downgrade. Analyst Commentary Recent Street research around ADMA Biologics reflects both optimism about the company’s setup and fresh caution around execution and valuation, which is feeding directly into the trimmed price targets.Narrative Update • Apr 20
ADMA: Long Term Guidance And Buybacks Will Counter Post Short Report Caution
Analysts have trimmed their view on ADMA Biologics, cutting the consensus price target by $6 to reflect increased caution following recent downgrades and questions raised after a short report, even as long term profitability assumptions and P/E expectations remain broadly steady. Analyst Commentary Recent research updates point to a more cautious tone around ADMA Biologics, with bearish analysts trimming price targets and shifting ratings to reflect higher perceived risk following the short report and subsequent uncertainty.Narrative Update • Apr 05
ADMA: Long Term Guidance And Buybacks Will Support Post Short Report Upside
Analysts have nudged their price target for ADMA Biologics to $17.00, reflecting updated assumptions on revenue growth, profit margins, discount rate and future P/E following recent downgrades and reduced clarity cited in Street research. Analyst Commentary Recent Street research has taken a more cautious stance on ADMA Biologics, with bearish analysts reassessing their views after a short report introduced fresh uncertainty around the story.Narrative Update • Mar 22
ADMA: Long Term Revenue Guidance And Buybacks Will Support Bullish Outlook
Analysts are maintaining their $17.00 price target on ADMA Biologics, as only minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions do not materially change their view of the stock's valuation. What's in the News ADMA completed a share repurchase program announced on May 7, 2025, buying back a total of 1,919,070 shares, or 0.8% of shares, for US$31.92 million, including 590,422 shares, or 0.25% of shares, for US$8.91 million between October 1, 2025 and December 31, 2025 (Key Developments).Narrative Update • Mar 08
ADMA: Multiyear Revenue Guidance And Share Buybacks Will Support Future Upside
Analysts have modestly revised their price target on ADMA Biologics to $30.00, reflecting updated assumptions around slightly lower revenue growth, a higher profit margin, and a somewhat lower future P/E multiple. The fair value estimate remains at $30.00.Narrative Update • Feb 21
ADMA: Long-Term Revenue Outlook And Margins Will Support Current Fair Value
Analysts have modestly fine tuned their price target on ADMA Biologics to $17.00, citing slightly higher modeled revenue growth and profit margins, along with a marginally lower future P/E assumption, as key drivers of their updated view. What's in the News ADMA Biologics issued earnings guidance for 2027, expecting total revenue of approximately $775m.Narrative Update • Feb 07
ADMA: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value target for ADMA Biologics at $30.00. They have made small adjustments to inputs such as discount rate, revenue growth, profit margin, and future P/E to fine-tune their underlying assumptions rather than alter the headline valuation.Narrative Update • Jan 24
ADMA: Raised Revenue Guidance And Margin Gains Will Offset Higher Discount Rate
Analysts have raised their price target on ADMA Biologics to US$17.00, reflecting updated views on slightly higher projected revenue growth, a stronger profit margin profile, a modest adjustment to the discount rate, and a lower assumed future P/E multiple. What's in the News Raised preliminary unaudited earnings guidance for fiscal 2025, with total revenue now expected between approximately US$510 million and US$511 million (Corporate Guidance: Raised).Narrative Update • Jan 10
ADMA: Raised Long Term Revenue Guidance And Buybacks Will Support Upside
Analysts have trimmed their price target on ADMA Biologics from US$35.00 to US$30.00, pointing to updated assumptions around a modestly higher discount rate, slightly lower revenue growth expectations, a higher projected profit margin, and a lower future P/E multiple. What's in the News ADMA Biologics completed a share repurchase program announced on May 7, 2025, buying back a total of 1,328,648 shares, or 0.56% of shares, for US$23.01 million, including 512,411 shares, or 0.21%, for US$8.03 million from July 1 to September 30, 2025 (Key Developments).Narrative Update • Dec 25
ADMA: Higher Discount Rate Will Outweigh Stronger Revenue Outlook
Analysts have trimmed their price target on ADMA Biologics from 19.24 dollars to 17.00 dollars, citing the need for a slightly higher discount rate and modestly lower long term margin assumptions, despite a somewhat stronger revenue growth outlook and more conservative future valuation multiples. What's in the News Raised revenue guidance for fiscal 2025 to at least $510 million, up from more than $500 million previously (Company guidance) Increased fiscal 2026 revenue outlook to at least $630 million, compared with prior guidance of $625 million or more (Company guidance) Introduced long term guidance targeting total annual revenue of $1.1 billion or more by 2029, with expectations for earnings growth above current margin levels (Company guidance) Completed a share repurchase of 1,328,648 shares, or 0.56 percent of outstanding shares, for $23.01 million under the buyback program announced on May 7, 2025, including 512,411 shares repurchased in the most recent tranche (Buyback update) Valuation Changes Fair Value Estimate trimmed from $19.24 to $17.00, a modest downward revision of roughly 12 percent.Narrative Update • Dec 11
ADMA: Share Repurchases And Long Term Revenue Outlook Will Drive Future Upside
Narrative Update on ADMA Biologics Analysts have maintained their price target for ADMA Biologics at 27.25 dollars, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. This signals continued confidence in the company’s long term earnings trajectory and risk profile.Analysis Article • Dec 02
ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have had a really impressive month, gaining 25% after a shaky period...Narrative Update • Nov 27
ADMA: Share Repurchases And Rising Earnings Guidance Will Support Future Upside
Analysts have maintained their price target for ADMA Biologics at $27.25 per share, citing stable financial projections and consistent optimism regarding the company's growth prospects. What's in the News From July 1, 2025 to September 30, 2025, ADMA Biologics repurchased 512,411 shares, completing a total buyback of 1,328,648 shares for $23.01 million as announced in May 2025 (Key Developments).Narrative Update • Nov 12
ADMA: Buyback Activity And Margin Expansion Will Drive Robust Results
Analysts have increased their price target for ADMA Biologics to $27.25. They cite expectations for stronger revenue growth and higher profit margins, balanced against a slightly higher discount rate and declining future price-to-earnings multiples.Narrative Update • Oct 29
Share Repurchase And Higher Margins Will Drive Future Upside Potential
Analysts have slightly lowered their price target for ADMA Biologics from $27.81 to $27.25. They cited modest adjustments in financial assumptions, including revenue growth and profit margins.Narrative Update • Oct 14
Optimized Yield Process And Expanding Capacity Will Build Lasting Momentum
Analysts have lowered their price target for ADMA Biologics from $29.06 to $27.81, primarily because of slight adjustments in fair value and future price-to-earnings estimates. Revenue growth and profit margin projections remain largely unchanged.Seeking Alpha • Mar 21
ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Summary ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% year-over-year revenue increase, with strong gross profit margins and minimal R&D expenses, highlighting ADMA's efficient operations. Financial health is solid with $103.147 million in cash and manageable liabilities, supporting long-term growth and investment potential. Despite some overvaluation, ADMA's differentiated products, vertical integration, and strong patent portfolio justify a "buy" rating, with future R&D progress being critical. Read the full article on Seeking AlphaAnalysis Article • Feb 26
Revenues Not Telling The Story For ADMA Biologics, Inc. (NASDAQ:ADMA)
With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...Seeking Alpha • Feb 06
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
Summary ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030. With minimal risks and a strong competitive advantage, ADMA Biologics presents a compelling long-term investment opportunity, especially following the recent stock pullback. Read the full article on Seeking AlphaAnalysis Article • Dec 31
Does ADMA Biologics (NASDAQ:ADMA) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Dec 02
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
Summary ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company’s key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor concerns, but now appear resolved with KPMG’s appointment as ADMA’s new accounting firm. Thus, I think legal risks have subsided. Now, looking forward, SG-001 could also become a future growth driver if successfully researched and commercialized. Despite a premium valuation, I believe ADMA's growth potential in the $20 billion IG market by 2030 justifies a "Buy" rating for long-term investors. Read the full article on Seeking AlphaAnalysis Article • Nov 26
Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shareholders would be excited to see that the share price has had a great month...New Narrative • Nov 20
Valuation analysis
11-NOV-2024Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25)Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9,Analysis Article • Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have continued their recent momentum with a 27% gain in the last month...Seeking Alpha • Oct 02
ADMA Biologics: Riding High On ASCENIV's Success
Summary ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks. Despite high valuation, ADMA Biologics' diversified revenue streams and solid financial health justify maintaining a "buy" rating with a dollar-cost averaging strategy. Read the full article on Seeking AlphaAnalysis Article • Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for ADMA Biologics is US$26.20 based on 2 Stage Free Cash Flow to Equity Current...
New Narrative • Sep 03
ASCENIV Drives Revenue Surge, Shaping A Bright Future For The Biotech Leader
ADMA Biologics showcases rapid revenue growth and operational efficiency, with ASCENIV's success significantly impacting future growth.Analysis Article • Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
ADMA Biologics, Inc. ( NASDAQ:ADMA ) recently posted some strong earnings, and the market responded positively. We have...Seeking Alpha • Jul 27
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Summary ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company’s IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB. ADMA's revenue growth is driven by the expanding US immunoglobulin market, projected to exceed $20 billion by 2030. Despite a high valuation premium, I deem ADMA a "buy" for GARP biotech investors due to its revenue growth projections. Read the full article on Seeking AlphaAnalysis Article • Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have been powering on, with a gain of 25% in...Analysis Article • Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADMA Biologics fair value estimate is US$16.37 Current share...Analysis Article • May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
A week ago, ADMA Biologics, Inc. ( NASDAQ:ADMA ) came out with a strong set of quarterly numbers that could potentially...Seeking Alpha • May 12
Giving ADMA Biologics A Well-Deserved 'Booyah'
Summary ADMA Biologics reported stellar Q1 results after the bell on Thursday, May 9th, and the stock shot forward by 27% in trading on Friday. The company seems to be executing on all cylinders, and management ratcheted up forward guidance for both FY2024 and FY2025. Can the shares continue to rally after this 'Booyah' quarter? An updated analysis around ADMA Biologics follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 6.2x ADMA Biologics, Inc. ( NASDAQ:ADMA ) is definitely a...Analysis Article • Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 03
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Summary ADMA Biologics' stock has seen a significant rally, fueled by growth in plasma-derived biologics and improved financial health. Recent earnings highlight revenue growth, operational efficiencies, and a shift towards profitability, with notable progress in reducing operating expenses. Future growth is anticipated from Asceniv's market penetration and a promising pipeline, including a potential treatment for strep pneumonia. Despite a substantial stock price increase, ADMA's solid fundamentals and strategic market position justify an upgrade to a "Buy" recommendation. Investors are advised to approach ADMA with caution, considering its speculative nature, while also acknowledging its potential for high returns within a diversified portfolio. Read the full article on Seeking AlphaSeeking Alpha • Jan 19
ADMA Biologics: On A Roll Entering 2024
Summary ADMA Biologics enters 2024 on quite a roll and the stock should continue to do well going forward. The company has recently completed the build of its plasma collection network, turned the corner on profitability, and redid its credit facility in a positive way. Why momentum for ADMA Biologics should continue in 2024 is highlighted below. Read the full article on Seeking AlphaAnalysis Article • Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Key Insights The projected fair value for ADMA Biologics is US$9.56 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, ADMA Biologics, Inc. ( NASDAQ:ADMA ) shares have been powering on, with a gain of 30% in...Shareholder Returns
| ADMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -5.2% | -0.9% |
| 1Y | -42.7% | 38.0% | 13.9% |
Return vs Industry: ADMA underperformed the US Biotechs industry which returned 38% over the past year.
Return vs Market: ADMA underperformed the US Market which returned 13.9% over the past year.
Price Volatility
| ADMA volatility | |
|---|---|
| ADMA Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ADMA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ADMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 644 | Adam Grossman | www.admabiologics.com |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.
ADMA Biologics, Inc. Fundamentals Summary
| ADMA fundamental statistics | |
|---|---|
| Market cap | US$2.07b |
| Earnings (TTM) | US$168.96m |
| Revenue (TTM) | US$512.28m |
12.2x
P/E Ratio4.0x
P/S RatioIs ADMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADMA income statement (TTM) | |
|---|---|
| Revenue | US$512.28m |
| Cost of Revenue | US$180.81m |
| Gross Profit | US$331.47m |
| Other Expenses | US$162.51m |
| Earnings | US$168.96m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 64.71% |
| Net Profit Margin | 32.98% |
| Debt/Equity Ratio | 48.2% |
How did ADMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 03:12 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ADMA Biologics, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Prem Chulaki | CrispIdea |